{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:39:12Z","timestamp":1793817552912,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jaci.2023.09.032","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T03:55:27Z","timestamp":1696391727000},"page":"265-274.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Interim analysis: Open-label extension study of leniolisib for patients with APDS"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7881-6902","authenticated-orcid":false,"given":"V. Koneti","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Kulm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"\u0160ediv\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Plebani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Schuetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Shcherbina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgil A.","family":"Dalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Trizzino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Zharankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanvin","family":"Orpia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"K\u00f6rholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Lougaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Rodina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kath","family":"Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Bradt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Relan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Lenardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulbu","family":"Uzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2023.09.032_bib1","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3389\/fimmu.2018.02043","article-title":"The treatment of activated PI3Kdelta syndrome","volume":"9","author":"Coulter","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib2","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.jaci.2019.03.017","article-title":"PI3K pathway defects leading to immunodeficiency and immune dysregulation","volume":"143","author":"Nunes-Santos","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib3","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41590-018-0182-3","article-title":"Hyperactivated PI3Kdelta promotes self and commensal reactivity at the expense of optimal humoral immunity","volume":"19","author":"Preite","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib4","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3389\/fimmu.2018.01758","article-title":"Genetic defects in phosphoinositide 3-kinase delta influence CD8(+) T cell survival, differentiation, and function","volume":"9","author":"Cannons","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib5","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1084\/jem.20141759","article-title":"Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K","volume":"211","author":"Lucas","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2023.09.032_bib6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1146\/annurev-immunol-032712-095946","article-title":"Signaling by the phosphoinositide 3-kinase family in immune cells","volume":"31","author":"Okkenhaug","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib7","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage","volume":"342","author":"Angulo","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.09.032_bib8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","article-title":"Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: a cohort study","volume":"138","author":"Elkaim","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib11","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood.2019002072","article-title":"Increased activation of PI3 kinase-delta predisposes to B-cell lymphoma","volume":"135","author":"Durandy","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2023.09.032_bib12","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1016\/j.jaip.2021.07.044","article-title":"Clinical manifestations and outcomes of activated phosphoinositide 3-kinase delta syndrome from the USIDNET cohort","volume":"9","author":"Oh","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.09.032_bib13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3389\/fimmu.2018.00543","article-title":"Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase delta syndrome: the European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase \u03b4 Syndrome Registry","volume":"9","author":"Maccari","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib14","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jaci.2016.09.040","article-title":"Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome","volume":"139","author":"Nademi","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib15","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaci.2021.04.036","article-title":"International\u00a0retrospective study of allogeneic hematopoietic cell transplantation\u00a0for activated PI3K-delta syndrome","volume":"149","author":"Dimitrova","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaci.2018.04.032","article-title":"Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase delta syndrome type 1","volume":"143","author":"Okano","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s12016-019-08738-9","article-title":"Clinical, immunological, and genetic features in patients with activated PI3Kdelta\u00a0syndrome (APDS): a systematic review","volume":"59","author":"Jamee","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib18","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S1470-2045(22)00300-X","article-title":"PI3K inhibitors in haematological malignancies","volume":"23","author":"Brown","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaci.2023.09.032_bib19","doi-asserted-by":"crossref","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","article-title":"Management of toxicity to isoform alpha-specific PI3K inhibitors","volume":"30","author":"Nunnery","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaci.2023.09.032_bib20","unstructured":"US Food & Drug Administration. FDA briefing document: phosphatidylinositol 3-kinase (PI3K) inhibitors in hematologic malignancies. Available at: https:\/\/www.fda.gov\/media\/157762\/download. Accessed October 19, 2023."},{"key":"10.1016\/j.jaci.2023.09.032_bib21","series-title":"Copiktra [package insert]. Las Vegas","year":"2021"},{"key":"10.1016\/j.jaci.2023.09.032_bib22","series-title":"Ukoniq [package insert]","year":"2021"},{"key":"10.1016\/j.jaci.2023.09.032_bib23","series-title":"Zydelig [package insert]","year":"2022"},{"key":"10.1016\/j.jaci.2023.09.032_bib24","series-title":"Aliqopa [package insert]","year":"2022"},{"key":"10.1016\/j.jaci.2023.09.032_bib25","series-title":"Piqray [package insert]","year":"2022"},{"key":"10.1016\/j.jaci.2023.09.032_bib26","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.4049\/jimmunol.2000326","article-title":"Seletalisib for activated PI3Kdelta syndromes: open-label phase 1b and extension studies","volume":"205","author":"Diaz","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib27","unstructured":"Safety, pharmacokinetic (PK) and pharmacodynamic (PD) study of repeat doses of inhaled nemiralisib in patients with APDS\/PASLI. Available at: https:\/\/clinicaltrials.gov\/study\/NCT02593539. Accessed October 19, 2023."},{"key":"10.1016\/j.jaci.2023.09.032_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2023.102201","article-title":"An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of activated PI3 kinase delta syndrome","volume":"79","author":"Begg","year":"2023","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaci.2023.09.032_bib29","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \u201cactivated PI3Kdelta syndrome\u201d-targeted therapy with the PI3Kdelta inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2023.09.032_bib30","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2022018546","article-title":"A randomized, placebo-controlled phase 3 trial of the PI3Kdelta inhibitor leniolisib for activated PI3Kdelta syndrome","volume":"141","author":"Rao","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2023.09.032_bib31","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.3389\/fimmu.2018.01924","article-title":"T cells that help B cells in chronically inflamed tissues","volume":"9","author":"Rao","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s10875-016-0279-0","article-title":"Health-related quality of life and health resource utilization in patients with primary immunodeficiency disease prior to and following 12 months of immunoglobulin G treatment","volume":"36","author":"Routes","year":"2016","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib33","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fped.2019.00353","article-title":"Inborn errors of immunity with immune dysregulation: from bench to bedside","volume":"7","author":"Delmonte","year":"2019","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaci.2023.09.032_bib35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1021\/acsmedchemlett.7b00293","article-title":"Discovery of CDZ173 (leniolisib), representing a structurally novel class of PI3K delta-selective inhibitors","volume":"8","author":"Hoegenauer","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jaci.2023.09.032_bib36","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutre","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaci.2023.09.032_bib37","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2023.09.032_bib38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nchembio0310-244b","article-title":"The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors","volume":"6","author":"Berndt","year":"2010","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jaci.2023.09.032_bib44","doi-asserted-by":"crossref","unstructured":"Cant AJ, Chandra A, Munro E, Rao VK, Lucas CL. PI3K\u03b4 Pathway dysregulation and unique features of its inhibition by leniolisib in activated PI3K\u03b4 syndrome and beyond [published online ahead of print, 2023 Sep 28]. J Allergy Clin Immunol Pract. 2023;S2213-2198(23)01046-2. https:\/\/doi.org\/10.1016\/j.jaip.2023.09.016","DOI":"10.1016\/j.jaip.2023.09.016"},{"key":"10.1016\/j.jaci.2023.09.032_bib39","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2023.09.032_bib40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2249.2010.04206.x","article-title":"Reference values for B cell\u00a0subpopulations from infancy to adulthood","volume":"162","author":"Morbach","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.clim.2009.05.020","article-title":"Refined characterization and reference values of the pediatric T- and B-cell compartments","volume":"133","author":"van Gent","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2023.09.032_bib42","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \u201cactivated PI3Kdelta syndrome\u201d-targeted therapy with the PI3Kdelta inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2023.09.032_bib43","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2022018546","article-title":"A randomized, placebo-controlled phase 3 trial of the PI3Kdelta inhibitor leniolisib for activated PI3Kdelta syndrome","volume":"141","author":"Rao","year":"2023","journal-title":"Blood"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923012447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923012447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:46:23Z","timestamp":1758793583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674923012447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0091674923012447"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2023.09.032","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interim analysis: Open-label extension study of leniolisib for patients with APDS","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2023.09.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}